Stock·NASDAQ·Technology
Roper Technologies Inc. (ROP)
- Market cap
- $37.85B
- P/E
- 15.76
- Dividend yield
- 0.95%
- Street target
- $422.00median of 19 analysts
- 52-week range
- $305.96 $519.10
The short version
Where ROP stands today, in four lines, and what CleaRank Financial AI makes of it.
ROP at a glance
Roper Technologies Inc. (ROP): Buy, 65/100 on CleaRank's AI score.
- Trend Mixed: the price is above its 200-day but below its 50-day moving average ($365.12 and $386.59).
- Earnings ROP beat estimates in 8 of its last 8 quarters, yet fell the next day after 4 of those beats.
- Insiders Insiders sold $20.5M and bought $5.6M over the last 18 months.
- Valuation P/E of 15.8 against 35.1 for the Technology sector: a discount to peers (-55%).
Figures as of October 18, 2026.
CleaRank Financial AI
Roper Technologies Inc. (ROP) carries a CleaRank rating of Buy and a model score of 65/100.
Valuation adds the most to that score: the P/E of 15.76 is 55.1% below the sector median, a discount to peers, and the P/S of 4.57 is 39.9% below the sector median. Revenue growth pulls the score down the most, with revenue up 8.50%, 15.7 percentage points slower than the sector median. Trend is mixed. The price sits 1.00% below its 50-day average of $386.59 yet 4.82% above its 200-day average of $365.12. The price fell 23.47% over the past year.
Only on CleaRank
Figures we compute ourselves from ROP's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
2/4Price above its 50-day average ›
The price of $382.71 is 1.0% below the 50-day simple moving average of $386.59.Price above its 200-day average ›
The price is 4.8% above the 200-day simple moving average of $365.12.50-day average above the 200-day ›
The 50-day average ($386.59) is 5.9% above the 200-day average ($365.12), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 36% of its 52-week range, between $305.96 and $519.10.
ROP share price
Pick a period: each tab shows how far ROP has moved over it, to the last close.
Today's trading
Where ROP sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
5/5P/E below the sector median ›
The trailing P/E of 15.76 is 55.1% below the Technology median of 35.1.P/S below the sector median ›
The price-to-sales ratio of 4.57 is 39.9% below the sector median of 7.6.Profitable over the last 12 months ›
Net income over the last 12 months was $2.5B on revenue of $8.3B, a net margin of 30.2%.Beat estimates in most recent reports ›
ROP beat the EPS estimate in 8 of its last 8 reports.Pays a dividend ›
The trailing dividend yield is 0.95%, or $3.64 a share a year.
Key statistics
The headline figures for ROP.
As of October 18, 2026, ROP trades at $382.71, with a market value of $37.85B, a P/E ratio of 15.76 and a dividend yield of 0.95%.
What the numbers say
CleaRank Financial AI's reading of ROP's valuation, growth and risks.
Against the 35.1 median P/E of Technology stocks, Roper Technologies Inc. (ROP)'s P/E of 15.76 is 55.1% below that median, which counts as a discount to peers. Measured against sales, the P/S of 4.57 is 39.9% below the sector median of 7.6.
Over the latest year, revenue expanded 8.50%, which leaves it 15.7 percentage points behind the Technology sector median of 24.2%. Even so, ROP converts sales into earnings well, with a net margin of 30.24% and an operating margin of 27.73%. Its return on equity of 13.07% is below the sector median of 13.4%. Debt-to-equity stands at 0.61, and the trailing dividend yield is 0.95%, or $3.64 per share each year.
ROP's most recent quarterly report, released on July 23, 2026, showed EPS of $5.38. Analysts had expected $5.29, so the company cleared the estimate by 1.70%. In the first session after the report, the share price went up 3.44%.
The record is a clean sweep: 8 beats in 8 reports; even so, 4 of those 8 beats were followed by a lower share price the next session. Looking ahead, analysts expect EPS of $22.22 this fiscal year (growth of 11.1%) and $24.38 the year after (growth of 9.7%).
On a typical day the price of ROP shifts by 1.58%, the 30-day standard deviation of its daily returns. The price is 26.27% below its 52-week high of $519.10. Over the last 18 months, insider sales totalled $20.5M against $5.6M of purchases; planned sales and tax sales on vesting shares make selling a weaker signal than buying.
ROP against the Technology sector
How ROP compares with the median Technology stock CleaRank tracks.
Price to earnings vs sector: ROP trades at a notable discount to sector peers (-55%), which may indicate undervaluation or specific company headwinds.
Return vs XLK: Since May 6, 2025, ROP has lost 32.8% against a gain of 71.7% for XLK.
Performance against XLK
ROP and the Technology sector fund over the same days.
Revenue and earnings
How much ROP sells, and how much of it becomes profit.
Revenue growth: Revenue grew 12.3% in FY2025 to $7.9B, from $7.0B a year earlier.
Profit margin: The net margin was 19.4% in FY2025, down from 22.0% the year before.
Profitable: ROP earned $1.5B in FY2025.
Earnings reality check
Did ROP beat what analysts expected, and how did the stock react?
Earnings record: ROP beat the analyst estimate in 8 of the last 8 quarters.
Market reaction: The stock fell in the first session after 4 of those 8 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Jul 23, 2026after close | $5.29 | $5.38 | +1.70% | +3.44% | +9.61% |
| Apr 23, 2026after close | $4.99 | $5.16 | +3.41% | -2.85% | -2.46% |
| Jan 27, 2026after close | $5.14 | $5.21 | +1.36% | -2.41% | -5.54% |
| Oct 23, 2025after close | $5.11 | $5.14 | +0.59% | -0.24% | -7.62% |
| Jul 21, 2025after close | $4.83 | $4.87 | +0.83% | +2.16% | +1.29% |
| Apr 28, 2025after close | $4.74 | $4.78 | +0.84% | +0.76% | +3.47% |
| Jan 30, 2025after close | $4.73 | $4.81 | +1.69% | +0.89% | +2.25% |
| Oct 23, 2024after close | $4.53 | $4.62 | +1.99% | -0.15% | +0.79% |
As of October 18, 2026, ROP has beaten the analyst EPS estimate in 8 of its last 8 reported quarters and fell in the first trading session after 4 of those beats; its latest report, on July 23, 2026, came in 1.70% above the estimate and the stock moved +3.44% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
2/3RSI not overbought or oversold ›
The 14-day RSI is 58.7, in neutral territory.RSI above 50 ›
An RSI of 58.7 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is negative, so the 12-day average is below the 26-day average.
CleaRank AI analysis of ROP
The score, the reasoning behind it, and what could move the price next.
The price of ROP sits between its two moving averages: at $382.71, it is 4.82% above the 200-day average ($365.12) and 1.00% below the 50-day average ($386.59). The 50-day average runs 5.88% above the 200-day average, a gap that would narrow if the price stays under the shorter average. The price is at 36% of its 52-week range, between a low of $305.96 and a high of $519.10.
Recent gains sit against a weaker longer record: the price rose 1.83% over the past month, rose 5.39% over the past three months and fell 23.47% over the past year. On momentum, the 14-day RSI reads 58.7, in the neutral zone, with the MACD line negative.
Earnings beat ›
The July 23, 2026 report beat the EPS estimate by 1.70%, and the share price rose 3.44% in the first session after it.
Source: Earnings report, July 23, 2026Analyst upgrade ›
Argus Research upgraded it to Buy from Hold on August 6, 2026.
Source: Analyst action, Argus Research, August 6, 2026
New analyst coverage ›
BMO Capital started coverage at Market Perform on July 10, 2026.
Source: Analyst action, BMO Capital, July 10, 2026
- The two closest levels to watch are the 50-day SMA at $386.59, which sits above the price, and the 20-day EMA at $370.76, which sits below it.
- The 14-day RSI reads 58.7, in the neutral zone, with the MACD line negative; readings above 70 or below 30 mark stretched momentum.
- After the July 23, 2026 report the share price rose 3.44% in the first session; ROP beat estimates in 8 of the last 8 reports.
The trend is mixed: ROP is above its 200-day average at $365.12 but below its 50-day average at $386.59. A close above the 50-day would turn both signals up, and a close below the 200-day would turn both down. In the meantime the price sits between the 20-day EMA ($370.76) underneath and the 50-day SMA ($386.59) overhead.
With a 14-day RSI of 58.7, the stock sits in the neutral zone, which runs from 40 to 60.
Technical indicators
Momentum and trend for ROP, from its daily closes.
As of October 18, 2026, with ROP at $382.71, its 14-day RSI is 58.7 (neutral territory), its 50-day simple moving average is $386.59 and its 200-day is $365.12.
Calculated by CleaRank on daily closes as of October 18, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What ROP moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 18, 2026, ROP's 1-year correlation of daily returns is +0.31 with S&P 500 (SPY), +0.18 with Nasdaq 100 (QQQ), +0.08 with Bitcoin (BTC) and -0.06 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
2/3Most analysts rate it a buy ›
7 of 19 analysts rate it a buy or strong buy, 10 a hold and 2 a sell.Median target above the price ›
The median 12-month target of $422.00 is 10.3% above the price.More buy ratings than three months ago ›
7 of 19 rate it a buy now, against 7 of 20 three months ago.
ROP Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Aug 18, 2026 | RBC Capital | Reiterates | Sector Perform |
| Aug 6, 2026 | Argus Research | Upgrade | Buy |
| Jul 29, 2026 | JP Morgan | Maintains | Underweight |
| Jul 24, 2026 | RBC Capital | Maintains | Sector Perform |
| Jul 24, 2026 | Piper Sandler | Maintains | Overweight |
| Jul 10, 2026 | BMO Capital | Initiates | Market Perform |
As of October 18, 2026, 19 Wall Street analysts cover ROP: 7 rate it a buy or strong buy, 10 a hold and 2 a sell or strong sell. Their 12-month price targets range from $335.00 to $550.00, with a median of $422.00, 10.3% above the price of $382.71.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
ROP trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from ROP's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much ROP tends to move, against the market and on its own.
The long record
ROP's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
2/4Average daily move under 2% ›
The price has moved 1.58% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 46.0%, from March 2025 to May 2026; the price is still 34.6% below that peak.Most 1-year holds ended higher ›
72% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $23,593, against $41,793 in the S&P 500 (SPY).
ROP Drawdowns & Recovery
As of October 18, 2026, ROP's worst peak-to-trough fall over the last 10 years with dividends reinvested was -46.0% (March 2025 to May 2026); it is still 34.6% below that peak, and 72% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into ROP in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: ROP trailed the S&P 500 over this period: $23,593 against $41,793.
A $10,000 investment in ROP in October 2016 would be worth about $23,593 today with dividends reinvested, compared with about $41,793 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to ROP, and which have not.
Strongest month, November: an average of +5.51%, up in 9 of 10 years.
Weakest month, September: an average of -4.31%, up in 2 of 10 years.
This month, October: has averaged -1.19%, up in 4 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, ROP's strongest calendar month has been November (average +5.51%, up in 9 of 10 years) and its weakest September (average -4.31%, up in 2 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in ROP, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in ROP today could grow to about $19,890 by 2036 in the base case, with a 90th-percentile outcome near $52,400 and a 10th-percentile outcome around $7,550. The simulation models price only; at today's 0.95% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
ROP Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $504 for ROP by 2030 in the base case, from $383 today (1.3x over 4 years). The 10th-percentile path ends near $273. These are outcomes of a Monte Carlo simulation run on ROP's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $302 | $410 | $557 | |
| 2028 | $285 | $439 | $677 | |
| 2029 | $277 | $470 | $800 | |
| 2030 | $273 | $504 | $930 | |
| 2031 | $272 | $540 | $1,071 |
Method: a lognormal simulation of ROP's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
ROP insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: Insiders bought $5.6M on the open market and sold $20.5M.
As of October 18, 2026, ROP insiders reported 8 open-market sales worth $20.5M and 3 open-market purchases worth $5.6M over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Oct 1, 2026 | Abhijit Dubey
Director
|
Grant | 632 | - |
| Sep 15, 2026 | Irene M Esteves
Director
|
Grant | 78 | - |
| Jul 27, 2026 | John K Stipancich
Officer
|
Sell | 2.0K | $758.1K |
| Jul 27, 2026 | John K Stipancich
Officer
|
Option | 2.0K | $457.7K |
| Jul 24, 2026 | Richard F. Wallman
Director
|
Sell | 6.4K | $2.3M |
| May 20, 2026 | Shellye L Archambeau
Director
|
Grant | 1.2K | - |
| May 20, 2026 | Amy Woods Brinkley
Director
|
Grant | 1.2K | - |
| May 20, 2026 | Irene M Esteves
Director
|
Grant | 1.2K | - |
| May 20, 2026 | Robert D. Johnson
Director
|
Grant | 1.2K | - |
| May 20, 2026 | Thomas Patrick Joyce Jr
Director
|
Grant | 1.2K | - |
| May 20, 2026 | John Francis Murphy
Director
|
Grant | 1.2K | - |
| May 20, 2026 | Laura Glover Thatcher
Director
|
Grant | 1.2K | - |
| May 20, 2026 | Richard F. Wallman
Director
|
Grant | 1.2K | - |
| Mar 16, 2026 | Shellye L Archambeau
Director
|
Grant | 92 | - |
| Mar 16, 2026 | Irene M Esteves
Director
|
Grant | 85 | - |
| Mar 16, 2026 | Thomas Patrick Joyce Jr
Director
|
Grant | 85 | - |
| Mar 16, 2026 | Richard F. Wallman
Director
|
Grant | 92 | - |
| Mar 10, 2026 | Brandon L Cross
Officer
|
Grant | 1.2K | - |
| Feb 6, 2026 | Thomas Patrick Joyce Jr
Director
|
Buy | 1.4K | $501.8K |
| Dec 8, 2025 | Richard F. Wallman
Director
|
Grant | 4.0K | - |
| Dec 1, 2025 | Jason Conley
Chief Financial Officer
|
Sell | 6.0K | $2.7M |
| Dec 1, 2025 | Jason Conley
Chief Financial Officer
|
Option | 6.0K | $1.0M |
| Nov 12, 2025 | Amy Woods Brinkley
Director
|
Buy | 1.2K | $540.9K |
| Nov 12, 2025 | Laurence Neil Hunn
Chief Executive Officer
|
Buy | 10.0K | $4.5M |
| Nov 11, 2025 | Laurence Neil Hunn
Chief Executive Officer
|
Sell | 30.0K | $13.3M |
| Nov 11, 2025 | Laurence Neil Hunn
Chief Executive Officer
|
Option | 30.0K | $5.6M |
| Sep 15, 2025 | Shellye L Archambeau
Director
|
Grant | 64 | - |
| Sep 15, 2025 | Irene M Esteves
Director
|
Grant | 59 | - |
| Sep 15, 2025 | Thomas Patrick Joyce Jr
Director
|
Grant | 59 | - |
| Sep 15, 2025 | Richard F. Wallman
Director
|
Grant | 64 | - |
| Aug 15, 2025 | Robert D. Johnson
Director
|
Sell | 400 | $210.2K |
| Jul 24, 2025 | John K Stipancich
General Counsel
|
Grant | 100 | - |
| Jul 23, 2025 | John K Stipancich
General Counsel
|
Sell | 1.5K | $846.3K |
| Jul 23, 2025 | John K Stipancich
General Counsel
|
Option | 1.5K | $343.3K |
| Jul 22, 2025 | Richard F. Wallman
Director
|
Sell | 352 | $195.8K |
| Jul 22, 2025 | Richard F. Wallman
Director
|
Grant | 4.0K | - |
| Jun 11, 2025 | Shellye L Archambeau
Director
|
Grant | 675 | - |
| Jun 11, 2025 | Amy Woods Brinkley
Director
|
Grant | 675 | - |
| Jun 11, 2025 | Irene M Esteves
Director
|
Grant | 675 | - |
| Jun 11, 2025 | Robert D. Johnson
Director
|
Grant | 675 | - |
| Jun 11, 2025 | Thomas Patrick Joyce Jr
Director
|
Grant | 675 | - |
| Jun 11, 2025 | John Francis Murphy
Director
|
Grant | 675 | - |
| Jun 11, 2025 | Laura Glover Thatcher
Director
|
Grant | 675 | - |
| Jun 11, 2025 | Richard F. Wallman
Director
|
Grant | 675 | - |
| May 5, 2025 | Christopher B Wright
Director
|
Sell | 350 | $200.3K |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 18, 2026.